Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-MT-7117 in Healthy Male Subjects
NCT03503266Phase 1Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoints: Maximum observed plasma concentration, Time to Cmax and 7 more. Started Mar 2018; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NCT03503266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03503266.